A Phase II Trial of AZD6244 (NSC #748727, IND #77782) in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Principal Investigator
John Farley, MD
Status
Terminated
Date Opened To Accrual
December 17 2007
Date Closed to Accrual
November 23 2009
Date of Study Termination
November 05 2020
Disease Site
Gynecologic [GY]
Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To examine the tumor response rate of patients on AZD6244 (NSC #748727).
To examine the acute toxicity of AZD6244 (NSC #748727) during the first course of treatment using CTCAE version 3.0.
To define the pharmacokinetic profile for AZD6244, 100 mg administered orally twice daily.
Patient Population
Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum.
Target Accrual
51
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.